HC Wainwright Predicts Alector’s Q2 Earnings (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) – Stock analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for Alector in a research note issued on Friday, May 8th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.22) per share for the quarter, up from their previous forecast of ($0.37). The consensus estimate for Alector’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Alector’s Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.95) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at ($0.90) EPS.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%.The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $9.67 million.

ALEC has been the subject of a number of other research reports. Morgan Stanley restated an “underweight” rating and set a $2.00 target price on shares of Alector in a report on Monday, May 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Alector in a report on Monday, May 4th. Wall Street Zen upgraded Alector from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research upgraded Alector from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a report on Tuesday, March 10th. Finally, Cantor Fitzgerald upgraded Alector from a “neutral” rating to an “overweight” rating in a report on Wednesday, April 15th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.63.

Alector Stock Down 2.4%

Alector stock opened at $2.05 on Tuesday. The business has a fifty day moving average of $2.30 and a two-hundred day moving average of $1.85. The company has a quick ratio of 5.25, a current ratio of 5.25 and a debt-to-equity ratio of 0.80. The firm has a market cap of $227.61 million, a P/E ratio of -1.72 and a beta of 0.64. Alector has a twelve month low of $1.01 and a twelve month high of $3.40.

Institutional Investors Weigh In On Alector

Large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its position in shares of Alector by 42.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 283,817 shares of the company’s stock valued at $610,000 after purchasing an additional 84,691 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Alector by 15.8% in the 1st quarter. Bank of New York Mellon Corp now owns 252,297 shares of the company’s stock valued at $542,000 after purchasing an additional 34,435 shares during the last quarter. Diversified Trust Co raised its position in shares of Alector by 83.6% in the 1st quarter. Diversified Trust Co now owns 25,895 shares of the company’s stock valued at $56,000 after purchasing an additional 11,793 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Alector in the 4th quarter valued at approximately $34,000. Finally, Invesco Ltd. raised its position in shares of Alector by 45.3% in the 4th quarter. Invesco Ltd. now owns 279,468 shares of the company’s stock valued at $436,000 after purchasing an additional 87,157 shares during the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.